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Dear Editor of Food and Chemical Toxicology,
The Société Française de Pathologie Toxicologique (SFPT, French
Society of Toxicologic Pathology, toxpathfrance.org) is a non gov-
ernmental/non proﬁt organization formed by veterinarians, physi-
cians, pharmacists and biologists specialized in veterinary and
toxicologic pathology. Its aim is to promote knowledge in pathol-
ogy, toxicology and laboratory animal sciences for safety studies
of drugs, chemicals and food products, and the role of the pathol-
ogist in the study design and data interpretation. As such, the SFPT
feels compelled to point out weaknesses in the paper by Séralini
et al. (2012), the number and importance of which make the study
reported very difﬁcult to interpret scientiﬁcally. We are aware that
more arguments can be found in other scientiﬁc disciplines.
Before concentrating on veterinary and pathology aspects, we
wish to brieﬂy comment on two points. Regarding the statement
that ‘‘The authors declare that there are no conﬂicts of interest’’,
we respectfully disagree: Pr Gilles-Eric Séralini being President of
the Scientiﬁc Board of the CRIIGEN, and the CRIIGEN having been
a ‘‘major support’’ of the study, it seems to us that this should have
been disclosed. Regarding the English, several native-English
speaking colleagues complained about the difﬁculty to read the
text because of many gross errors in expression: we consider that
the journal reviewers could have alerted the authors on this point.
In our opinion, the study as reported (Ethics, §2.1) demonstrate
a critical failure in the ethical supervision. First, it is not clear that
the protocol was reviewed by a Committee of Animal Ethics/Insti-
tutional Animal Care and Use Committee, a basic requirement in
the industry to even allow the purchasing of laboratory animals.
‘‘Animal experiments were performed according to ethical guide-
lines. . .’’ is not the same than stating that the protocol and the pro-
cedures were approved by an Ethical Committee. This is especially
important in view of the statement that 31 parameters were ana-
lyzed (Biochemical analyses, §2.4): the quantity of blood removed
is not indicated, and this could have had an effect on the well being
of the animals and on their sanitary status. Clear guidelines of lim-
its on blood sampling are available in the literature (Diehl et al.,
2001), but it is impossible to know if they were followed in the
study. Then, the choice of a low number of animals per group,
thereby not following published guidelines (OECD, 2008, 2009),
can be criticized as the data generated cannot be analyzed accord-
ing to the state of the art methods and animals will have been used
for no purpose, thus not respecting the humane principle of reduc-
tion (Russell and Burch, 1959). Last but not least, we were shocked
at reading the ethical rules followed for euthanasia (‘‘25% body
weight loss, tumors over 25% body weight. . .’’ leading to euthana-0278-6915 2012 Elsevier Ltd.
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the tumors, with skin erosions and ulcerations, having certainly an
impact on movement, feeding and pain, is unacceptable under
well-known guidelines (Workman et al. 1998). This should have
led to a much earlier euthanasia with respect to ethical humane
concerns and casts doubts about the ‘‘careful monitoring’’ (Ana-
tomopathological observations, §3.2) of animals. No argument,
apparently to leave tumors develop as much as possible, should
have prevailed. Again this demonstrates a lack of understanding
of animal physiology and ethics, and a lack of supervision by the
Ethical Committee and by a site veterinarian (‘‘vétérinaire sani-
taire’’, a function mandatory under French law, see Article R203-
1 5). We are surprised that these major ethical issues were not
clariﬁed during the review that the paper underwent before ap-
proval for publication. Moreover, given that the tumors seen on
the photos are not speciﬁc for treated animals and can be seen
in aged rats, they are not informative, their inclusion is highly
objectionable and we can only guess they regretfully serve public
relation but not scientiﬁc purposes.
We lack a clear understanding of the procedure followed for the
pathologic examination of tissues. Especially, we have no idea, gi-
ven the authors’ afﬁliations, of who performed this pathologic
examination. Also, for toxicology and carcinogenicity studies like
this one, there are best practices available for primary reading
(Crissman et al. 2004) and for peer review (Morton et al., 2010).
The errors due to the lack of use of internationally recognized
nomenclature and diagnostic criteria (as can be seen in the use
of the term nephroblastoma in legend from Table 2 being called
Wilm’s tumor in the text, and in its erroneous assessment as
GMO-related while it is an embryonal tumor found in young ro-
dents) could have been avoided by following those best practices.
The SFPT has among its members scientists from the industry,
academia and also independent consultants. It would be happy
to supply names of renowned colleagues, French or foreign, with
a track record of assessment of toxicology and carcinogenicity
studies, who would have increased the quality of the pathological
assessment and the overall value of this study.
We already hinted at deﬁciencies in the study design: from a
statistical perspective, this long term study is largely underpow-
ered with only 10 animals per sex per group, while the accepted
guidelines (OECD, 2008, 2009) recommend using groups of at least
50 animals per sex per group, and deﬁne strict survival rate criteria
that the groups must respect for the results to be considered valid.
With mortality rates of 50 or 70% in some groups, we wonder
whether these criteria were consistently met. As far as we under-
stand, all results are based on descriptive analyses such as percent-
age calculation, but there was no thorough mortality analysis (how
to compare 3/10 with 5/10?) nor tumor incidence and date of onset
analysis with recognized statistical methods (Peto et al., 1980). Not
taking into account the high variability (because of the small size
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sions non-meaningful and leads the authors to a gross over inter-
pretation of the pathology data.
We are puzzled by the inclusion of organ weights: in carcino-
genesis studies, geriatric changes and, at later stages, the develop-
ment of tumors confound the usefulness of organ weight data,
which are therefore not recommended (OECD, 2008). We are also
puzzled by the mention of 2 tumors beginning to ‘‘reach a large
size . . . up to 600 days earlier in 2male groups eating the GM
maize’’: we understand that those 2 males are the ones affected
early with the nephroblastomas mentioned above, and this con-
ﬁrms us in our analysis of the origin and absence of treatment-
relationship of those tumors.
As the paper reports a de facto carcinogenesis study, we expected
to see some of the classical objectives of such a study type: the
identiﬁcation of the carcinogenic properties of a chemical; the iden-
tiﬁcation of target organs; the characterization of a dose–response
relationship; the identiﬁcation of a no-observed (adverse) effect le-
vel (NO(A)EL); the prediction of carcinogenic effects of a chemical at
human exposure levels; understanding the mode of action for treat-
ment-related ﬁndings. We do not ﬁnd in the results and in the dis-
cussion all the information necessary to meet these objectives;
especially the non-conventional data reporting, with only an extract
of the study data, and the data presentation, with merging of vari-
ous pathological entities in Table 2 and focus on non-relevant ﬁnd-
ings, prevent us to make a scientiﬁc evaluation of the objectives
discussed above. A full incidence list of all tumors by type, sex
and group would have been more useful than a full plate of photos.
We spotted other errors in the Anatomopathological observa-
tions (§3.2): presenting incomplete neoplastic and non-neoplastic
ﬁndings; considering hepatic foci of altered cells as necrotic foci;
hepatic congestion being not relevant if the rats were found dead
or moribund; diagnosing macroscopic necrotic foci; presenting
common neoplasms in treated animals as treatment-speciﬁc; not
presenting historical data (particularly useful in this case given
the small group size); noting a difference between photos1 and 2
in Fig. 4, and reporting the increase in smooth endoplasmic retic-
ulum while this change should be regarded as adaptive to xenobi-
otic metabolism (in the absence of contrary evidence); not
presenting a mechanism for the increase in glycogen noted on
the EM photos (especially in the absence of fasting status of the
animals at euthanasia); lacking to critically discuss the pituitary
tumors and the mammary tumors (prolactin-dependent); lacking
to critically discuss the chronic progressive nephropathy in old
rats. This list is not exhaustive, but is enough to cast doubts about
the value of all the anatomopathological results.
In conclusion, the SFPT is deeply convinced that a thorough
evaluation of all products is necessary before marketing but also
during the product life, in order to guarantee as much as possible
human, animal and environment safety. However, given this study
presents serious deﬁciencies in the protocol, the procedures and
the interpretation of the results, the SFPT cannot support any of
the scientiﬁc claims drawn by the authors, and any relevance for
human risk assessment.This letter presents the consensus scientiﬁc opinion of the
Conseil d’Administration of the SFPT.
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Further reading
For all pathology data not substantiated by a reference, please refer to recent and
comprehensive toxicologic pathology textbooks, such as Greaves, 2012.
Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in
Drug Safety Evaluation, fourth ed. Academic Press, New York.
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